[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349444-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349444-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","structure-based-design-synthesis-and-biological-evaluation-of-oxadiazole-morpholine-hybrids-as-potent-parp-1-inhibitors-inducing-apoptosis-in-breast-cancer-cells","Structure-Based Design, Synthesis, and Biological Evaluation of Oxadiazole-Morpholine Hybrids as Potent PARP-1 Inhibitors Inducing Apoptosis in Breast Cancer Cells","","Poly(ADP-ribose) polymerase-1 (PARP-1) is central to repairing DNA single-strand breaks and is a validated therapeutic target in oncology. This study used structure-based drug design to develop and synthesize oxadiazole–morpholine hybrid compounds targeting the PARP-1 catalytic domain. The compounds were assessed for cytotoxicity in breast and ovarian cancer cells, PARP-1 inhibitory potency, and apoptosis induction. Compound 12a showed strong cytotoxicity and PARP-1 inhibition and promoted apoptotic death and cell-cycle alteration, supported by docking results.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/structure-based-design-synthesis-and-biological-evaluation-of-oxadiazole-morpholine-hybrids-as-potent-parp-1-inhibitors-inducing-apoptosis-in-breast-cancer-cells/349444/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/structure-based-design-synthesis-and-biological-evaluation-of-oxadiazole-morpholine-hybrids-as-potent-parp-1-inhibitors-inducing-apoptosis-in-breast-cancer-cells/349444.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological target does the study focus on, and why is it important?","Question",{"text":63,"@type":64},"The study targets PARP-1, a key enzyme involved in repairing DNA single-strand breaks. PARP-1 is established as a therapeutic target in cancer treatment due to its role in DNA repair and its dysregulation in tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the oxadiazole–morpholine hybrid compounds developed?",{"text":68,"@type":64},"A structure-based drug design approach was used to design a series of novel oxadiazole–morpholine hybrid compounds, followed by synthesis of the tested molecules.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the evaluation show for the most active compound (12a)?",{"text":72,"@type":64},"Compound 12a exhibited potent cytotoxic activity against MDA-MB-231 cells, strong PARP-1 inhibitory activity, and significant induction of apoptotic cell death. Flow cytometry also indicated changes in cell-cycle progression, while docking supported binding in the PARP-1 catalytic site.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349444,1790138303,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Drug Development Research   \nRESEARCH ARTICLE   \nStructure‐Based Design, Synthesis, and Biological Evaluation of Oxadiazole–Morpholine Hybrids as Potent PARP‐1 Inhibitors Inducing Apoptosis in Breast Cancer Cells  \nNader R. Albujuq1 | Khaled M. Darwish2,3  | Sherif Ashraf Fahmy4  | Buthaina Hussein5  | Ghada G. Kayed6 | Musa A. Said7 | Mohamed S. Nafie8,9, 10   \n1Department of Chemistry, School of Science, The University of Jordan, Amman, Jordan | 2Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt | 3Department of Medicinal Chemistry, Faculty of Pharmacy, Galala University, New Galala, Egypt | 4Department of Pharmacy, Institute of Pharmaceutics and Biopharmaceutics, Marburg University, Marburg, Germany | 5Department of Pharmacy, Faculty of Pharmacy, Al‐Zaytoonah University of Jordan, Amman, Jordan | 6Faculty of science, Zarqa University, Zarqa, Jordan | 7Department of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah, Saudi Arabia | 8Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, United Arab Emirates | 9Bioinformatics and Functional Genomics Research Group, Research, Institute of Sciences and Engineering (RISE), University of Sharjah, Sharjah, United Arab Emirates | 10Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt  \nCorrespondence: Nader R. Albujuq ([n.albujuq@ju.edu.jo](n.albujuq@ju.edu.jo)) | Sherif Ashraf Fahmy ([sherif.fahmy@pharmazie.uni-marburg.de](sherif.fahmy@pharmazie.uni-marburg.de)) | Mohamed S. Nafie ([mohamed.elsayed@sharjah.ac.ae](mohamed.elsayed@sharjah.ac.ae))  \nReceived: 17 March 2026 | Revised: 11 June 2026 | Accepted: 24 June 2026  \nFunding: Alexander von Humboldt‐Stiftung; Philipps‐Universität Marburg; University of Jordan  \nKeywords: apoptosis induction | breast cancer | oxadiazole | PARP‐1 inhibition | synthesis  \nABSTRACT  \nPoly(ADP‐ribose) polymerase‐1 (PARP‐1) plays a central role in the repair of DNA single‐strand breaks and represents an established therapeutic target in cancer treatment. In this study, a series of novel oxadiazole–morpholine hybrid compounds was designed and synthesized using a structure‐based drug design approach to target the catalytic domain of PARP‐1 . The synthesized compounds were evaluated for their cytotoxic activity against breast and ovarian cancer cells, PARP‐1 inhibitory potency, and apoptosis‐inducing effects. Among the tested compounds, 12a exhibited potent cytotoxic activity against MDA‐ MB‐231 cells (IC50 = 1.23 μM), surpassing the reference drug olaparib (IC50 = 3.45 μM) . Compound 12a also demonstrated strong PARP‐1 inhibitory activity (IC50 = 0.034 μM), comparable to olaparib (IC50 = 0.012 μM) . Flow cytometric analyses revealed that compound 12a significantly induced apoptotic cell death and altered cell cycle progression. Molecular docking studies suggested plausible binding interactions within the PARP‐1 catalytic site, supporting the observed biological activity. These findings identify oxadiazole–morpholine hybrids as promising scaffolds for further optimization as PARP‐1 inhibitors.  \n1 | Introduction  \nCancer remains a serious global health challenge that affects individuals of all ages in nearly all human populations. It is the second most prevalent cause of death throughout the world and still makes a significant contribution to high  \nmortality rates and increasing healthcare burden. According to the World Health Organization (WHO) and Global Cancer Observatory (GLOBOCAN) , in 2024, an estimated 20 million new cancer cases were recorded globally, with around 10 million deaths caused by disease‐related factors. This is a concerning indicator of the continued rise in cancer  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . Drug Development Research publish","cbCaiaDXoV5vjOLE","https://ap.wps.com/l/cbCaiaDXoV5vjOLE","pdf",2954622,23,"English","# Introduction\n# Drug Design and Synthesis\n## Biological Evaluation\n## Cytotoxicity and Apoptosis Assays\n# Results and Discussion\n## PARP-1 Inhibitory Activity\n## Cell Cycle Effects\n## Molecular Docking\n# Conclusion","[{\"question\":\"What biological target does the study focus on, and why is it important?\",\"answer\":\"The study targets PARP-1, a key enzyme involved in repairing DNA single-strand breaks. PARP-1 is established as a therapeutic target in cancer treatment due to its role in DNA repair and its dysregulation in tumors.\"},{\"question\":\"How were the oxadiazole–morpholine hybrid compounds developed?\",\"answer\":\"A structure-based drug design approach was used to design a series of novel oxadiazole–morpholine hybrid compounds, followed by synthesis of the tested molecules.\"},{\"question\":\"What did the evaluation show for the most active compound (12a)?\",\"answer\":\"Compound 12a exhibited potent cytotoxic activity against MDA-MB-231 cells, strong PARP-1 inhibitory activity, and significant induction of apoptotic cell death. Flow cytometry also indicated changes in cell-cycle progression, while docking supported binding in the PARP-1 catalytic site.\"}]","Structure-Based Design, Synthesis, and Biological Evaluation of Oxadiazole-Morpholine Hybrids as Potent PARP-1 Inhibitors Inducing Apoptosis in Breast Cancer Cells | PDF",1790083330,58,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dbb8cf453f64aeedaa0ae0a1e81be8e.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5738443c7f1ed38024896bac846d8308.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/896f54a9b0b25fd49c4e8aa7dd706573.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be746df7036a7a46cb4b0173bf67af48.webp",980,1287]